马西替坦治疗不可手术慢性血栓栓塞性肺动脉高压(MERIT-1):多中心2期随机双盲安慰剂对照研究结果
MERIT-1为2期随机双盲安慰剂对照试验,纳入80例判定为不可手术的慢性血栓栓塞性肺动脉高压(CTEPH)患者,按1:1随机接受口服马西替坦10 mg每日一次或安慰剂。
要点
- 马西替坦组常见不良事件为外周水肿(9/40,23%)与血红蛋白下降(6/40,15%)
- 研究为2期探索性试验,样本量80例,需更大样本验证临床终点
核心结论
- 在不可手术的CTEPH患者中,马西替坦显著改善第16周静息PVR,且耐受性良好。
研究设计与样本
- 2期、多中心、随机、双盲、安慰剂对照试验(MERIT-1),在20个国家48家医院筛查186例,最终36家医院80例患者按1:1随机分组,马西替坦组与安慰剂组各40例。
- 纳入WHO功能分级II-IV级、PVR至少400 dyn·s/cm5、6分钟步行距离150-450 m的不可手术CTEPH患者。
- 马西替坦为口服10 mg每日一次;WHO功能分级III/IV级患者允许联用磷酸二酯酶5型抑制剂及口服或吸入前列环素类药物的治疗。
- 主要终点为第16周静息PVR,以基线PVR的百分比表示;主要分析纳入全部随机患者,安全性分析纳入至少接受一剂研究药物的患者。
主要发现
- 马西替坦组最常见不良事件为外周水肿(9/40,23%)和血红蛋白下降(6/40,15%)。
关键数值与推荐
- 主要终点为第16周静息PVR相对基线的百分比变化。
- 入组要求PVR至少400 dyn·s/cm5,6分钟步行距离150-450 m,WHO功能分级II-IV级。
- 马西替坦剂量为10 mg口服每日一次。
临床怎么用
- 对于判定为不可手术的CTEPH患者,可考虑马西替坦10 mg每日一次以改善肺血管阻力。
- 用药期间需关注外周水肿与血红蛋白下降等不良事件。
局限性
- 为2期试验,样本量仅80例,随访至第16周,主要终点为PVR替代指标,未报告硬终点。
- 研究由Actelion Pharmaceuticals Ltd资助。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. METHODS: The phase 2, double-blind, randomised, placebo-controlled MERIT-1 trial assessed macitentan in 80 patients with CTEPH adjudicated as inoperable. Patients identified as WHO functional class II-IV with a pulmonary vascular resistance (PVR) of at least 400 dyn·s/cm5 and a walk distance of 150-450 m in 6 min were randomly assigned (1:1), via an interactive voice/web response system, to receive oral macitentan (10 mg once a day) or placebo. Treatment with phosphodiesterase type-5 inhibitors and oral or inhaled prostanoids was permitted for WHO functional class III/IV patients. The primary endpoint was resting PVR at week 16, expressed as percentage of PVR measured at baseline. Analyses were done in all patients who were randomly assigned to treatment; safety analyses were done in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02021292. FINDINGS: Between April 3, 2014, and March 17, 2016, we screened 186 patients for eligibility at 48 hospitals across 20 countries. Of these, 80 patients in 36 hospitals were randomly assigned to treatment (40 patients to macitentan, 40 patients to placebo). At week 16, geometric mean PVR decreased to 73·0% of baseline in the macitentan group and to 87·2% in the placebo group (geometric means ratio 0·84, 95% CI 0·70-0·99, p=0·041). The most common adverse events in the macitentan group were peripheral oedema (9 [23%] of 40 patients) and decreased haemoglobin (6 [15%]). INTERPRETATION: In MERIT-1, macitentan significantly improved PVR in patients with inoperable CTEPH and was well tolerated. FUNDING: Actelion Pharmaceuticals Ltd.
引用
- Ghofrani HA, Simonneau G, D'Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017. PMID: 28919201. doi:10.1016/S2213-2600(17)30305-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。